Log in

NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, Forecast & News

-0.24 (-4.44 %)
(As of 02/17/2020 06:56 AM ET)
Today's Range
Now: $5.16
50-Day Range
MA: $4.27
52-Week Range
Now: $5.16
Volume1.21 million shs
Average Volume600,387 shs
Market Capitalization$116.67 million
P/E RatioN/A
Dividend YieldN/A
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BCLI



Sales & Book Value

Annual SalesN/A
Book Value$0.24 per share


Net Income$-13,950,000.00


Market Cap$116.67 million
Next Earnings Date2/18/2020 (Confirmed)

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) announced its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.03. View Brainstorm Cell Therapeutics' Earnings History.

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Brainstorm Cell Therapeutics.

How can I listen to Brainstorm Cell Therapeutics' earnings call?

Brainstorm Cell Therapeutics will be holding an earnings conference call on Tuesday, February 18th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for BCLI?

1 brokerages have issued twelve-month price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 74.4% from the stock's current price. View Analyst Price Targets for Brainstorm Cell Therapeutics.

What is the consensus analysts' recommendation for Brainstorm Cell Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Brainstorm Cell Therapeutics.

Has Brainstorm Cell Therapeutics been receiving favorable news coverage?

Media stories about BCLI stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Brainstorm Cell Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Brainstorm Cell Therapeutics.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 828,200 shares, an increase of 11.7% from the January 15th total of 741,600 shares. Based on an average daily trading volume, of 107,600 shares, the days-to-cover ratio is currently 7.7 days. Currently, 4.4% of the company's stock are sold short. View Brainstorm Cell Therapeutics' Current Options Chain.

Who are some of Brainstorm Cell Therapeutics' key competitors?

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:
  • Dr. Irit Arbel, Founder & Chairperson (Age 59)
  • Mr. Chaim Lebovits, Pres & CEO (Age 48)
  • Mr. Eyal Rubin, CFO & Treasurer (Age 43)
  • Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 61)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 42)

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.48%), Raymond James & Associates (0.54%), Bank of America Corp DE (0.10%), CFO4Life Group LLC (0.05%) and Tower Research Capital LLC TRC (0.05%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View Institutional Ownership Trends for Brainstorm Cell Therapeutics.

Which institutional investors are buying Brainstorm Cell Therapeutics stock?

BCLI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Raymond James & Associates, CFO4Life Group LLC, Tower Research Capital LLC TRC and Bank of America Corp DE. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View Insider Buying and Selling for Brainstorm Cell Therapeutics.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $5.16.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $116.67 million. The biotechnology company earns $-13,950,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.View Additional Information About Brainstorm Cell Therapeutics.

What is Brainstorm Cell Therapeutics' official website?

The official website for Brainstorm Cell Therapeutics is http://www.brainstorm-cell.com/.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]

MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  263 (Thanks for Voting!)
Underperform Votes:  187 (Thanks for Voting!)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel